Gainers
- Oncternal Therapeutics ONCT shares moved upwards by 7.0% to $2.0 during Monday's after-market session. The company's market cap stands at $98.8 million.
- CNS Pharmaceuticals CNSP shares increased by 5.25% to $0.63. The market value of their outstanding shares is at $17.6 million.
- Viracta Therapeutics VIRX shares rose 4.47% to $2.8. The market value of their outstanding shares is at $104.4 million.
- Protagenic Therapeutics PTIX stock moved upwards by 4.46% to $1.17. The company's market cap stands at $19.8 million.
- Minerva Neurosciences NERV stock rose 4.19% to $0.86. The market value of their outstanding shares is at $36.7 million.
- Vaccinex VCNX stock increased by 3.97% to $1.57. Vaccinex's trading volume hit 463.4K shares by close, accounting for 47.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $48.3 million.
Losers
- Sio Gene Therapies SIOX stock fell 6.8% to $1.09 during Monday's after-market session. At the close, Sio Gene Therapies's trading volume reached 73.5K shares. This is 12.6% of its average volume over the last 100 days. The company's market cap stands at $80.1 million.
- Alaunos Therapeutics TCRT stock fell 5.56% to $1.02. The market value of their outstanding shares is at $220.4 million.
- Calithera Biosciences CALA stock decreased by 5.39% to $0.61. Calithera Biosciences's trading volume hit 710.8K shares by close, accounting for 34.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $46.0 million.
- Biofrontera BFRI stock decreased by 4.13% to $3.25. The market value of their outstanding shares is at $48.9 million.
- NeuroBo Pharmaceuticals NRBO shares decreased by 3.85% to $1.0. The company's market cap stands at $26.5 million.
- 2seventy bio TSVT stock fell 3.17% to $18.08. The company's market cap stands at $422.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in